Citigroup’s Tevogen Inc. Common Stock TVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$194 Buy
43
+24
+126% +$294 ﹤0.01% 5581
2025
Q4
$308 Sell
19
-74
-80% -$1.92K ﹤0.01% 5619
2025
Q3
$3.65K Sell
93
-174
-65% -$8.56K ﹤0.01% 5326
2025
Q2
$16.7K Sell
267
-112
-30% -$6.38K ﹤0.01% 5116
2025
Q1
$20.5K Buy
379
+21
+6% +$1.38K ﹤0.01% 5087
2024
Q4
$18.5K Buy
358
+33
+10% +$2.15K ﹤0.01% 5285
2024
Q3
$5.99K Buy
325
+228
+235% +$6.67K ﹤0.01% 5338
2024
Q2
$3.49K Buy
+97
New +$6.32K ﹤0.01% 5295
2022
Q4
Sell
-8,086
Closed -$4.11M 5989
2022
Q3
$4.11M Buy
8,086
+5,000
+162% +$2.52M ﹤0.01% 1652
2022
Q2
$1.54M Hold
3,086
﹤0.01% 2295
2022
Q1
$1.54M Buy
+3,086
New +$1.53M ﹤0.01% 2567

Other funds holding TVGN

Citigroup's TVGN Position: Q1 2026 in Review

Citigroup increased its Tevogen Inc. Common Stock (TVGN) stake by 126% in Q1 2026, buying an estimated $294 and bringing the position to 43 shares worth $194. The position accounts for ﹤0.01% of the portfolio, ranked #5581.

Citigroup first reported a position in TVGN in Q1 2022 and has held it in 11 quarters since. The position peaked at $4.11M in Q3 2022. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • Citigroup held 43 shares of Tevogen Inc. Common Stock worth $194 as of Q1 2026.
  • Citigroup bought 24 Tevogen Inc. Common Stock shares in Q1 2026, an estimated $294.
  • Tevogen Inc. Common Stock made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5581 holding.
  • Citigroup first reported a position in Tevogen Inc. Common Stock in Q1 2022 and has held it in 11 quarters since.
  • Citigroup's Tevogen Inc. Common Stock position peaked at $4.11M in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Tevogen Inc. Common Stock as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.